Pfizer names Cecile Guegan chief financial officer
Pfizer Inc. has appointed Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026.
Key points
- Pfizer’s board of directors unanimously elected Cecile Guegan as chief financial officer and executive vice president.
- The appointment does not signal a change in corporate strategy or financial performance.
Appointment of permanent finance executive
Pfizer’s board of directors unanimously elected Cecile Guegan as chief financial officer and executive vice president. Guegan previously served as interim chief financial officer, effective August 16, 2026.
Guegan’s annual base salary is $1,300,000. She is also eligible for a target cash incentive of $1,300,000, which represents 100% of her annual salary. In this role, she oversees audit, treasury, investor relations, tax, and other corporate financial functions.
Annual compensation for the chief financial officer
Significance of the appointment for shareholders
The appointment does not signal a change in corporate strategy or financial performance. This is a standard corporate decision to appoint a permanent executive following service on an interim basis.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Pfizer
A notification in your browser or on your phone when we publish about Pfizer. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
